Global MEK Inhibitors Market 2019-2023

MEK阻害剤の世界市場:メキニスト、コテリック、メクトビ

◆タイトル:Global MEK Inhibitors Market 2019-2023
◆商品コード:IRTNTR31830
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年8月10日
◆ページ数:136
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア太平洋、ヨーロッパ、北米、その他
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社の本調査レポートでは、MEK阻害剤の世界市場について調べ、MEK阻害剤の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、MEK阻害剤の市場規模をセグメンテーション別(製品別(メキニスト、コテリック、メクトビ)、)と地域別(アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社はMEK阻害剤の世界市場規模が2019-2023期間中に年平均8%成長すると予測しています。
・サマリー
・レポートの範囲
・MEK阻害剤の市場状況
・MEK阻害剤の市場規模
・MEK阻害剤の市場予測
・MEK阻害剤の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(メキニスト、コテリック、メクトビ)
・MEK阻害剤の顧客状況
・主要地域別市場規模:アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

Global MEK Inhibitors Market 2019-2023: About the market
MEK is a drug that inhibits the mitogen-activated extracellular signal-regulated kinase. Technavio’s MEK inhibitors market analysis considers sale from MEKINIST, COTELLIC, and MEKTOVI. Our analysis also considers the MEK inhibitors in Asia, Europe, North America, and ROW. In 2018, the MEKINIST segment had a significant share, and this trend is expected to continue over the forecast period. Factors such as treatment of melanoma, presence of protein kinase, and cellular proliferation will play a significant role in the MEKINIST segment to maintain its market position. Also, our global MEK inhibitors market report looks at factors such as high target affinity and specificity of MEK inhibitors, use of combination therapies, and strategic alliances. However, the uncertainties in abundance of substitutes, adverse effects of MEK inhibitors and stringent regulations may hamper the growth MEK inhibitors market over the forecast period.
Global MEK Inhibitors Market: Overview
High target affinity and specificity of MEK inhibitors
MEK inhibitors are the small molecule targeted therapy drugs that are used for the treatment of carcinomas. These drugs act on MEK directly and hinder its activity and help in decreasing the growth of the tumor. This demand for high target affinity and specificity of MEK inhibitors will lead to the expansion of the global MEK inhibitors market at a CAGR of over 8% during the forecast period.
Use of protein biomarkers in the diagnosis of NSCLC
Protein biomarkers help in detecting tumors as they can differentiate between the morphological as well as the chemical features of the protein in normal cells and abnormal cells. A major factor that is increasing the popularity of protein biomarkers for the detection of NSCLC is their efficacy in the diagnosis of the condition. The use of predictive protein biomarkers can also lower the cost of treatment as well as the adverse effects associated with it. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global MEK inhibitors market during the forecast period 2019-2023, click here.
Competitive Landscape
With the presence of a few major players, global MEK inhibitors market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading MEK inhibitors manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc.
Also, global MEK inhibitors, market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• MEKINIST – Market size and forecast 2018-2023
• COTELLIC – Market size and forecast 2018-2023
• MEKTOVI – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Special drug designations
• Expanded application
• Use of protein biomarkers in diagnosis of NSCLC
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca Plc
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: MEKINIST – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: MEKINIST – Year-over-year growth 2019-2023 (%)
Exhibit 22: COTELLIC – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: COTELLIC – Year-over-year growth 2019-2023 (%)
Exhibit 24: MEKTOVI – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: MEKTOVI – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Country-wise age-standardized rate of melanomas in Europe 2018
Exhibit 35: Country-wise prevalence rate of NSCLC in Europe 2008
Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Alternative therapies based on MEK inhibitors for various oncology indications
Exhibit 47: Side effects of MEK and BRAF inhibitors
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Drug designations
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AstraZeneca Plc – Vendor overview
Exhibit 56: AstraZeneca Plc – Business segments
Exhibit 57: AstraZeneca Plc – Organizational developments
Exhibit 58: AstraZeneca Plc – Geographic focus
Exhibit 59: AstraZeneca Plc – Key offerings
Exhibit 60: AstraZeneca Plc – Key customers
Exhibit 61: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 62: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 63: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 64: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 65: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 66: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 67: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 68: Novartis AG – Vendor overview
Exhibit 69: Novartis AG – Business segments
Exhibit 70: Novartis AG – Organizational developments
Exhibit 71: Novartis AG – Geographic focus
Exhibit 72: Novartis AG – Segment focus
Exhibit 73: Novartis AG – Key offerings
Exhibit 74: Novartis AG – Key customers
Exhibit 75: Ono Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 76: Ono Pharmaceutical Co. Ltd. – Business segments
Exhibit 77: Ono Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 78: Ono Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 79: Ono Pharmaceutical Co. Ltd. – Key offerings
Exhibit 80: Ono Pharmaceutical Co. Ltd. – Key customers
Exhibit 81: Pfizer Inc. – Vendor overview
Exhibit 82: Pfizer Inc. – Business segments
Exhibit 83: Pfizer Inc. – Organizational developments
Exhibit 84: Pfizer Inc. – Geographic focus
Exhibit 85: Pfizer Inc. – Segment focus
Exhibit 86: Pfizer Inc. – Key offerings
Exhibit 87: Pfizer Inc. – Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors



【掲載企業】

AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., and Pfizer Inc.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[MEK阻害剤の世界市場:メキニスト、コテリック、メクトビ]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆